Protection against virus variants and the vaccination of young people will be the focus of the vaccination campaign in the future.
But for this the EU has to dig deeper into its pockets.
Munich - Currently only people over the age of 16 are vaccinated in Germany.
It is becoming increasingly clear, however, that this can only be the first step in the vaccination campaign.
Young people should also soon be protected from the corona virus.
For this, the vaccine from Biontech and Pfizer is currently the first choice - this has an impact on the price.
The German vaccine manufacturer Biontech and its US partner Pfizer recently applied to the European approval authority EMA for approval of their preparation for children and adolescents aged twelve to 15 years.
It will apparently be more expensive to sell than the previous preparation.
The two pharmaceutical companies have negotiated a price premium of around 50 percent per dose with the European Union (EU).
This is reported by
Die
Welt
.
This emerges from a letter from the Ministry of Finance to the budget committee of the German Bundestag.
Corona vaccination from Biontech - EU contains 900 million doses of the new edition of Biontech
Accordingly, the EU Commission has now negotiated the third contract with the vaccine manufacturers. From December 2021, 900 million cans are to be delivered to the member states. According to the letter, Germany is said to have received a proportion of 165 million cans and has undertaken to pay 3.83 billion euros for them. If you calculate the price per dose, that's 23.20 euros instead of the previous 15.50 euros.
According to the letter, this contract is intended to ensure an “adequate supply of adequate vaccines against Covid-19 for the coming years”.
In addition, the agreed delivery contains "adapted vaccines against virus variants and for children".
The contract probably also contains an option for 900 million more cans.
It is to be presented to the member states in the next few days.
There was initially no official confirmation of the significant price increase.
Big surcharge for the Biontech vaccination - these are the reasons for the increase
+
The vaccine from Biontech / Pfizer will probably be more expensive in the future.
© Christof Stache / AFP
But according to
Die Welt,
there are reasons for the price premium that would also be cited in Brussels.
The new contract places much stricter requirements on manufacturers.
The company must regularly adapt the vaccine to new virus variants.
There is also a monthly delivery obligation.
So far there has only been a quarterly one.
In addition, the price for future doses cannot be compared with the current one, as the EU pre-financed the development of the vaccines and their clinical testing last year.
The construction of production facilities was also financially supported.
This is reflected in the price.
(mam)
List of rubric lists: © Christof Stache / AFP
